Swedish pharmaceutical company Xspray Pharma (STO:XSPRAY) announced on Friday the launch of new bioequivalence studies with a slightly modified formulation of HyNap-Dasa.
Xspray Pharma's leading product candidates, HyNap-Dasa and HyNap-Nilo, are stable amorphous versions of the blockbuster cancer drugs Sprycel (dasatinib) and Tasigna (nilotinib). HyNap-Dasa is being developed in two versions, a generic and an improved version. HyNap-Nilo is being developed as an improved version and has received orphan drug status from the US Food and Drug Administration (FDA).
The new studies are being conducted on healthy volunteers with the objective to demonstrate that HyNap-Dasa is bioequivalent to Sprycel, in order for the company to be able to submit an abbreviated new drug application (ANDA) in the United States. Preliminary results are expected at the beginning of the second quarter.
The first study involves fasted healthy volunteers, while the second study, due to start in early February, will involve non-fasted healthy volunteers.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US